Description
Antibodies to Sm antigens (anti-Sm) are specific for systemic lupus erythematosus and are present in 30-40% of patients with this disease. Anti-Sm concentration does not correlate with the activity and clinical variants of systemic lupus erythematosus.
Antibodies to RNP antigens are antibodies to protein components of small nuclear ribonucleoprotein – U1RNA and are detected in mixed connective tissue diseases, less often in systemic lupus erythematosus and other rheumatic diseases.
Antibodies to SS-A antigens are most often detected in Sjogren's syndrome and systemic lupus erythematosus (SLE). In SLE, the production of these antibodies is associated with a specific set of clinical manifestations and laboratory abnormalities: photosensitization, Sjogren's syndrome, hyperproduction of rheumatoid factor.
Antibodies to SS-B antigens are detected in Sjogren's disease and syndrome and in the initial period of systemic lupus erythematosus developing in old age and associated with a low incidence of nephritis.
Antibodies to Scl-70 are more often detected in diffuse (40%), less often in limited (20%) forms of systemic scleroderma. They are highly specific for this disease and are a poor prognostic sign regarding the development of pulmonary fibrosis.
Anti-PM/Scl antibodies are a specific serological marker for a subgroup of patients with scleroderma (Scl), polymyositis (PM), and especially for those with a combination of symptoms of both diseases (PM/Scl).
Antibodies to proliferating cell nuclear antigen (PCNA) are one of the highly specific tests for detecting systemic lupus erythematosus.
Anticentromere antibodies (anti-CENT-B) are detected in patients with scleroderma, systemic lupus erythematosus, and rheumatoid arthritis.
Jo-1 antibodies (aminoacyl-tRNA synthetase) were first detected in the blood serum of patients with myositis. A large number of patients with antisynthetase syndrome suffer from interstitial lung disease, Raynaud's phenomenon, hyperkeratosis ("mechanic's hands"), and arthritis. This study can be used as a prognostic marker of disease progression.
Antibodies to histones are a type of antinuclear antibodies and are determined mainly in systemic lupus erythematosus.
Antibodies to nucleosomes are a more sensitive marker of systemic lupus erythematosus and are determined exclusively in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease.
Antibodies (Ab) to ribosomal P protein (Ribo P) are found in 10-20% of patients with SLE. These antibodies interact with ribosome phosphoproteins and are found predominantly in SLE patients with central nervous system involvement. Antibodies to ribosomes are detected in 20% of patients with SLE; their detection is specific for SLE proceeding with lupus psychosis.
Antibodies to mitochondrial M-2 antigens (representing a complex of enzymes on the inner mitochondrial membrane) are determined in primary biliary cirrhosis and indicate its severe course.
Period of execution
Within 10 days. The specified time does not include the day of biomaterial collection
Biomaterial type